Hypertension Center

Much Supply Confers Great Demand: Renal Denervation for Resistant Hypertension

A discussion of a challenging case of renal artery denervation for resistant hypertension.

By Brian Fulton, MD; Taisei Kobayashi, MD; and Jay Giri, MD, MPH

What’s Your Approach?

By Herb Aronow, MD, MPH, FACC, MSCAI, MSVM

How to Denervate With Current Renal Denervation Device Iterations

A step-by-step guide to renal denervation for the treatment of hypertension.

By Brian Fulton, MD; Jay Giri, MD, MPH; Debbie L. Cohen, MD; Herbert D. Aronow, MD, MPH; and Taisei Kobayashi, MD

Current Evidence for Catheter-Based Renal Denervation for Hypertension

A review of the evidence for a novel treatment for hypertension.

By Anna K. Krawisz, MD, and Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM

Team Approaches to Hypertension Management: New Opportunities for Interventionalists

A multidisciplinary approach to hypertension is necessary to achieve optimal outcomes, with interventionalists increasingly involved with the reemergence of promising nonpharmacologic options such as renal denervation.

By Klevin Roger L. Reyes, MD; Gizem Bilgili, MD; and Florian Rader, MD, MSc

Hypertension Headlines in 2020

What will the top mechanical therapy for hypertension stories coming out of major meetings in 2020 read? Endovascular Today sought prognostication from hypertension experts about therapeutic options in the coming years.

With Ajay J. Kirtane, MD, SM, FACC, FSCAI; Farrell O. Mendelsohn, MD; Melvin D. Lobo, MBChB, PhD, FRCP; Barry T. Katzen, MD; Marc Sapoval, MD, PhD; and Horst Sievert, MD

The Resistant Hypertension Quandary

A current look at what is known, key questions we should be asking, and some possible paths forward in research and practice.

By Graham D. Cole, MA, MRCP; James P. Howard, MA, MRCP; and Darrel P. Francis, MD, MA, FRCP

Searching for Answers in the Renal and Visceral Space

By Barry Katzen, MD, and Marc Sapoval, MD, PhD

SYMPLICITY HTN-3: Perspectives on How These Data Will Shape Future Application and Study of Renal Denervation

Ajay J. Kirtane, MD; Krishna J. Rocha-Singh, MD; and Prof. Darrel Francis discuss key data from the trial and its potential effect on patient care and the evaluation of interventional therapies for treatment-resistant hypertension.

SYMPLICITY HTN-3: Perspectives on How These Data Will Shape Future Application and Study of Renal Denervation

Ajay J. Kirtane, MD; Krishna J. Rocha-Singh, MD; and Prof. Darrel Francis discuss key data from the trial and its potential effect on patient care and the evaluation of interventional therapies for treatment-resistant hypertension.

SYMPLICITY HTN-3: Perspectives on How These Data Will Shape Future Application and Study of Renal Denervation

Ajay J. Kirtane, MD; Krishna J. Rocha-Singh, MD; and Prof. Darrel Francis discuss key data from the trial and its potential effect on patient care and the evaluation of interventional therapies for treatment-resistant hypertension.

Assessing Renal Denervation Studies

Editor-in-Chief of the European Heart Journal and EnligHTNment Principal Investigator, Thomas F. Lüscher, MD, FRCP, FESC, discusses study challenges and current literature.

Lessons Learned in Trial Design and Patient Selection

With many questions yet to be answered in the clinical study of renal denervation, Martin W. Bergmann, MD, PhD, FESC, discusses how previous results have shaped his practice.

Cautious Enthusiasm for Renal Denervation

Krishna J. Rocha-Singh, MD, FACC, FAHA, FSCAI, FSVM, shares his thoughts on the potential for this procedure and the methodical path required to get there.

Nonresponders to Renal Denervation for Resistant Hypertension

What do we know at this time, and what questions remain to be answered?

By Sameer Gafoor, MD; Jennifer Franke, MD; Stefan Bertog, MD; and Horst Sievert, MD

Microanatomy of the Renal Sympathetic Nervous System

The anatomic substrate for renal denervation.

By Farrell O. Mendelsohn, MD

Resistant Hypertension: Clinical Considerations and the Potential for Renal Denervation

The current landscape of major clinical trials and treatment.

By Vikas Kapil, MD, MRCP, PhD, and Melvin D. Lobo, MD, FRCP, PhD

Identifying Opportunity in Challenge

By Barry T. Katzen, MD